BPM31510T

BPM31510T is a topical pharmaceutical formulation containing ubidecarenone (Coenzyme Q10; CoQ10), developed by BPGbio for the treatment of epidermolysis bullosa (EB) and other rare diseases. It is designed to support wound healing in EB by targeting cellular and mitochondrial processes, specifically influencing key pathways involved in inflammation, cell proliferation, and tissue remodeling. The drug delivers CoQ10 directly to mitochondria in skin cells, leading to increased ATP generation and enhanced metabolic activity in fibroblasts and keratinocytes. BPM31510T has demonstrated a favorable safety profile and potential efficacy for improving wound healing in early clinical trials. It has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for EB[1][3][5][10].

Other names

BPM31510 topicalBPM-31510 topicalBPM 31510 topicalBPM31510 3% cream